Every Form 4 that Benitec Biopharm (BNTC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BNTC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BNTC filings page.
Benitec Biopharma Inc. director J. Kevin Buchi reported a charitable stock gift. On June 29, 2026, he transferred 51,813 shares of Benitec Biopharma Inc. common stock to a donor-advised fund sponsored by a Section 501(c)(3) charitable organization as a bona fide gift at no stated price. After this transfer, he directly holds 52,097 common shares. This is a non-market, charitable disposition rather than an open-market sale.
Benitec Biopharma Inc. director David Matthew Friedman was granted stock options linked to his board service. The award covers 35,000 options to buy Benitec common stock at an exercise price of $11.45 per share, expiring on May 26, 2036.
The options will vest in full on the earlier of immediately before Benitec’s next annual stockholder meeting or May 26, 2027. According to the disclosure, Friedman is a Managing Director of Suvretta Capital Management, which manages Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd. The options are held for the benefit of these funds, and Friedman disclaims beneficial ownership, while the funds and Suvretta Capital may be deemed to have an indirect pecuniary interest in the award.
Benitec Biopharma Inc. director Sharon Mates received a grant of stock options covering 31,500 shares of common stock. The options were awarded on January 22, 2026 at an exercise price of $12.83 per share, with no cash paid at grant.
These options are held directly and give the right to buy Benitec common stock in the future. According to the terms, the options will vest on the earlier of the company’s next annual stockholders’ meeting or December 1, 2026, tying the award to a medium-term service period on the board.
Benitec Biopharma Inc. (BNTC) reported a new stock option grant to its Chief Operating Officer, Sophie Mukadam, in an ownership filing. On 11/18/2025, she received options to purchase 500,000 shares of Benitec common stock at an exercise price of $13.53 per share, expiring on 11/18/2035. These options are scheduled to vest in 16 substantially equal quarterly installments beginning on March 31, 2026, meaning the award vests gradually over four years while she remains in her role.
Benitec Biopharma Inc. (BNTC) reported an equity award to its Chief Executive Officer and director, Jerel A. Banks, on a Form 4. On November 18, 2025, he received 450,000 stock options with an exercise price of $13.53 per share, giving him the right to buy Benitec common stock at that price.
The options have a long-term horizon, expiring on November 18, 2035. According to the filing, they will vest in 16 substantially equal quarterly installments, beginning on March 31, 2026. After this grant, Jerel A. Banks beneficially owned 450,000 stock options, held directly.
Benitec Biopharma Inc. (BNTC) reported a stock option grant to director and Chief Financial Officer Megan Boston. On 11/18/2025, she received options to purchase 200,000 shares of common stock at an exercise price of $13.53 per share, expiring on 11/18/2035.
The options will vest in 16 substantially equal quarterly installments beginning on March 31, 2026, meaning the award vests gradually over four years. The filing indicates she holds these options directly, reflecting a standard equity-based compensation grant that aligns executive incentives with shareholder interests.
Benitec Biopharma (BNTC) reported insider purchases by joint filers associated with Suvretta Capital. On 11/07/2025, the reporting persons acquired 730,370 shares of common stock at $13.5 per share and separately acquired 751,111 shares at $13.5. The holdings following these transactions were reported as 9,538,175 shares and 1,819,812 shares, respectively. The positions are listed as indirect ownership, and the filers are identified as a Director and 10% Owner. Additional explanatory notes are referenced in Exhibit 99.1.
Benitec Biopharma (BNTC) reported an insider equity award. A director received options to purchase 28,517 shares on 11/05/2025 at an exercise price of $15.78 per share. These options were granted for $0 and expire on 11/05/2035. The award will vest in full on the earlier of immediately prior to the company’s 2026 annual meeting of stockholders or November 5, 2026. Following the grant, the director holds 28,517 derivative securities directly.